Our Publications on Antibody-Drug Conjugates

Selected publications by Dr Borys Shor display the citations in Pubmed

1: Betts AM, Haddish-Berhane N, Tolsma J, Jasper P, King LE, Sun Y, Chakrapani S, Shor B, Boni J, Johnson TR. Preclinical to Clinical Translation of Antibody- Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. AAPS J. 2016 Sep;18(5):1101-1116. doi: 10.1208/s12248-016-9929-7. Epub 2016 May 19. PMID: 27198897.

2: Shor B, Kahler J, Dougher M, Xu J, Mack M, Rosfjord E, Wang F, Melamud E, Sapra P. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. Clin Cancer Res. 2016 Jan 15;22(2):383-94. doi: 10.1158/1078-0432.CCR-15-1166. Epub 2015 Aug 28. PMID: 26319086.

3. Mack, M., Kahler, J., Shor, B., Ritchie, M., Dougher, M., Sung, M. and Sapra, P. (2016). Lysosomes and Antibody–Drug Conjugates. In Lysosomes: Biology, Diseases, and Therapeutics (eds F.R. Maxfield, J.M. Willard and S. Lu). https://doi.org/10.1002/9781118978320.ch17

4: Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015 Oct;67(2 Pt A):107-16. doi: 10.1016/j.molimm.2014.09.014. Epub 2014 Oct 7. PMID: 25304309.

5: He H, Ratnayake AS, Janso JE, He M, Yang HY, Loganzo F, Shor B, O’Donnell CJ, Koehn FE. Cytotoxic Spliceostatins from Burkholderia sp. and Their Semisynthetic Analogues. J Nat Prod. 2014 Aug 22;77(8):1864-70. doi: 10.1021/np500342m. PMID: 25098528.

6: Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther. 2013 Jun;138(3):452-69. doi: 10.1016/j.pharmthera.2013.03.004. Epub 2013 Mar 15. PMID: 23507041.

Selected publications by Drs Nathan Tumey & Dhaval Shah display the citations in Pubmed

1: Jackson CP, Fang S, Benjamin SR, Alayi T, Hathout Y, Gillen SM, Handel JP, Brems BM, Howe JM, Tumey LN. Evaluation of an ester-linked immunosuppressive payload: A case study in understanding the stability and cleavability of ester- containing ADC linkers. Bioorg Med Chem Lett. 2022 Nov 1;75:128953. doi: 10.1016/j.bmcl.2022.128953. Epub 2022 Sep 1. PMID: 36058468.

2: Fang S, Brems BM, Olawode EO, Miller JT, Brooks TA, Tumey LN. Design and Characterization of Immune-Stimulating Imidazo[4,5-c]quinoline Antibody-Drug Conjugates. Mol Pharm. 2022 Sep 5;19(9):3228-3241. doi: 10.1021/acs.molpharmaceut.2c00392. Epub 2022 Jul 29. PMID: 35904247.

3: Miller JT, Vitro CN, Fang S, Benjamin SR, Tumey LN. Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers. Bioconjug Chem. 2021 Apr 21;32(4):842-858. doi: 10.1021/acs.bioconjchem.1c00124. Epub 2021 Mar 31. PMID: 33788548.

4: Liu S, Shah DK. Physiologically Based Pharmacokinetic Modeling to Characterize the Effect of Molecular Charge on Whole-Body Disposition of Monoclonal Antibodies. AAPS J. 2023 Apr 28;25(3):48. doi: 10.1208/s12248-023-00812-7. PMID: 37118220.

5: Chang HP, Le HK, Shah DK. Pharmacokinetics and Pharmacodynamics of Antibody- Drug Conjugates Administered via Subcutaneous and Intratumoral Routes. Pharmaceutics. 2023 Apr 3;15(4):1132. doi: 10.3390/pharmaceutics15041132. PMID: 37111619.

6: Chang HP, Li Z, Shah DK. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody- Drug Conjugate in Mice. Pharm Res. 2022 Jan;39(1):1-24. doi: 10.1007/s11095-021-03162-1. Epub 2022 Jan 19. PMID: 35044590.

7: Bussing D, Sharma S, Li Z, Meyer LF, Shah DK. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor. AAPS J. 2021 Apr 15;23(3):56. doi: 10.1208/s12248-021-00584-y. PMID: 33856579.23: Chang HP, Cheung YK, Shah DK. Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE). J Clin Med. 2021 Mar 23;10(6):1332. doi: 10.3390/jcm10061332. PMID: 33807057; PMCID: PMC8004929.